Changes in Hong Kong stocks | Yasheng Pharmaceutical (06855) rose more than 5%, and many clinical advances will be presented at the ASH Annual Meeting and will receive an oral report when APG-5918 is first announced

The Zhitong Finance App learned that Yasheng Pharmaceutical (06855) increased by more than 5%. As of press release, it rose 5.08% to HK$29.78, with a turnover of HK$146.293 million.

^{According to the news, Yasheng Pharmaceutical announced that several of the company's clinical and preclinical research advances were selected for the 68th American Society of Hematology (ASH) annual meeting, involving the first third-generation BCR-ABL inhibitor olevatinib (trade name: Nellick®), the first domestically produced original Bcl-2 inhibitor approved for marketing in China (trade name: Rishentol®), PRC2/} The four varieties of EED inhibitor APG-5918 and BTK degrader APG-3288 fully demonstrate the company's deep layout and global innovation strength in the field of hematologic oncology. It is worth noting that APG-5918 first published clinical data and received an oral report.

At this ASH annual conference, APG-5918 will present its clinical data on the efficacy and safety of relapsed/refractory T-cell lymphoma (R/R TCL) in the form of an oral report for the first time. R/R TCL has strong disease heterogeneity. Some patients are resistant to existing chemotherapy and targeted treatments, clinical treatment options are limited, and there are significant unmet medical needs. As a novel EED inhibitor, APG-5918 has shown encouraging anti-tumor activity and manageable safety in early clinical studies, and is expected to provide a new epigenetic targeted treatment option for such patients with difficult to treat TCL.